Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study

Racial differences in antiretroviral treatment responses remain incompletely explained and may be a consequence of differential pharmacokinetics (PK) associated with race. Raltegravir, an inhibitor of HIV-1 integrase, is commonly used in the treatment of HIV-infected patients, many of whom are Afric...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wohl, David A., Dumond, Julie B., Blevins, Suzanne, Pittard, Donna, Ragan, David, Wang, Ruili, Massengale, Kelley, Walsh, Kendall, Floris-Moore, Michelle, Eron, Joseph J., Richardson, Amy, Hudgens, Michael G., Kashuba, Angela D. M.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2013
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553727/
https://ncbi.nlm.nih.gov/pubmed/23183440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01826-12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires